Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Capitol Capsule: 'Innovative' Value-Based Pricing Strategies: Biopharma's Savior?

This article was originally published in Scrip

Executive Summary

With US insurers and pharmacy benefit managers (PBMs) increasingly becoming more and more aggressive about demanding better discounts and rebates from drug manufacturers and imposing more restrictions on what medicines the payers will include on their formularies, to survive, biopharmaceutical firms must bite the bullet and negotiate under value-based pricing schemes, said Dan Mendelson, CEO of the Washington-based analysis and consulting firm Avalere Health.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts